GLP-1 in Aesthetics: Compounding, Sourcing & Legal Status

The FDA maintains an active shortage list for both semaglutide and tirzepatide. When a drug is in shortage, the FDA grants temporary compounding authority under Section 503A of the FDCA to licensed pharmacies—allowing them to compound these drugs without pre-approval, provided they meet specific conditions (licensed pharmacy, licensed prescriber, no commercial advantage, etc.). However, this authority is temporary and conditional: it expires when the shortage ends. Check the FDA's official Drug Shortage Database (fda.gov/drugs/drug-shortages) weekly, as status changes affect your legal sourcing options. A shortage ending means compounded versions lose their legal shield—you cannot then dispense compounded GLP-1s unless you have a FDA-approved NDA or ANDA, which does not exist for compounded semaglutide or tirzepatide. Verify current shortage status before ordering or dispensing.

Approved branded products (Novo Nordisk's Ozempic, Wegovy; Eli Lilly's Mounjaro, Zepbound) are legal to prescribe and dispense if you hold appropriate licensure and follow state pharmacy/prescriber rules. Compounded versions are legal only during FDA shortage periods and only if sourced from a licensed 503A pharmacy that compounds under shortage authority. Do not source compounded GLP-1s from unlicensed compounders, online-only operations, or suppliers claiming to bypass shortage rules. Verify your pharmacy partner's state pharmacy board license and ask them to confirm they are operating under active FDA shortage compounding authority. Many practices have been caught sourcing from illegal or unregistered compounders. If you prescribe and dispense (rather than refer), you must ensure the supply chain is documented and compliant. Consult your state medical board and state pharmacy board for specific rules in your jurisdiction.

The FDA, state medical boards, and state pharmacy boards have escalated enforcement against unlicensed injection practices and illegal compounding operations. Recent cases include criminal prosecution of unlicensed med spa operators and civil actions against compounders operating outside shortage authority. Risks include: loss of license, criminal charges, civil liability, and patient harm claims. The DEA and state boards also scrutinize prescribing patterns—unusually high volumes of GLP-1 prescriptions to non-diabetic, non-obese patients may trigger audits. Document clear medical indications, obtain informed consent, and maintain records showing your supply source is licensed and compliant. If you offer GLP-1 services, ensure your staff are trained on proper injection technique, adverse event reporting, and contraindications. Unlicensed staff performing injections expose you to significant liability.

Medical aesthetics industry leaders have publicly acknowledged that GLP-1 use causes facial fat loss (colloquially 'semaglutide face'), which can accelerate visible aging and create demand for fillers and other procedures. This is a documented side effect, not a contraindication—but it is a disclosure obligation. Obtain informed consent that explicitly addresses the risk of facial volume loss, the potential need for concurrent or follow-up aesthetic procedures, and the timeline for reversal (which may be slow or incomplete). Document this conversation in the patient record. Consider offering complementary aesthetic services (fillers, biostimulators, skin treatments) as part of a bundled GLP-1 program, but price and market these transparently. Avoid implying that aesthetic procedures are required or inevitable; let patients decide. This transparency also protects you from claims of predatory upselling.

Prescribing authority varies by state and profession. Physicians, nurse practitioners, and physician assistants can prescribe GLP-1s in all states (subject to DEA registration if applicable, though GLP-1s are not controlled). Dispensing (handing the patient a physical supply) is more restricted: some states allow physicians to dispense from their office; others require a pharmacy intermediary. Nurse injectors and aestheticians cannot prescribe or dispense—they can only administer under a physician's prescription and supervision. Check your state medical board and state pharmacy board websites for specific rules. Some states require a collaborative practice agreement between the prescriber and the injector. Telehealth prescribing of GLP-1s is legal in many states but subject to state-specific telemedicine rules (e.g., some require an in-person visit first). Do not assume national rules apply; state law governs.

If you offer GLP-1 services, establish a monitoring protocol: baseline weight, BMI, blood glucose (if indicated), blood pressure, and renal function; follow-up visits at 4–6 weeks and then monthly or quarterly. Document contraindications (personal/family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, pregnancy, severe renal impairment). Report serious adverse events (pancreatitis, severe hypoglycemia, allergic reactions) to the FDA MedWatch program and notify the patient's primary care physician. Keep records for at least 7 years. If a patient experiences complications (e.g., dehydration, acute kidney injury, injection site infection), document your response and any referrals. This record-keeping protects you in litigation and demonstrates due diligence to regulators. Consider requiring patients to sign an acknowledgment of risks and a consent to off-label use if you are prescribing GLP-1s for weight loss in non-diabetic patients (which is common but technically off-label for some formulations).